{"schema_version":"secwatch.filing_event.v1","accession":"0001559053-22-000017","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2022-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.190247+00:00","generated_at":"2026-06-26T04:39:38.947027+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Prothena's PRX012 granted FDA Fast Track designation for Alzheimer's treatment","bullets":["FDA Fast Track designation for PRX012, a next-generation anti-amyloid beta antibody for Alzheimer's.","PRX012 is currently in Phase 1 clinical study; designed for subcutaneous administration.","Fast Track may enable more frequent FDA interactions and eligibility for Accelerated Approval and Priority Review.","Prothena CEO Gene Kinney stated PRX012 has potential to lead a paradigm shift in Alzheimer's treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001559053-22-000017","json":"https://secwatch.observer/filing/0001559053-22-000017.json","markdown":"https://secwatch.observer/filing/0001559053-22-000017.md","text":"https://secwatch.observer/filing/0001559053-22-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000155905322000017/0001559053-22-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000155905322000017/prta-20220426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T04:39:38.947027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}